FY2025 EPS Estimates for IN8bio Increased by Zacks Small Cap

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at Zacks Small Cap increased their FY2025 earnings estimates for IN8bio in a note issued to investors on Monday, March 17th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.17) for the year, up from their previous forecast of ($0.19). The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for IN8bio’s FY2026 earnings at ($0.18) EPS.

Separately, HC Wainwright dropped their price objective on shares of IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, March 14th.

IN8bio Price Performance

Shares of IN8bio stock opened at $0.23 on Thursday. The stock has a 50 day moving average price of $0.27 and a 200-day moving average price of $0.29. IN8bio has a one year low of $0.21 and a one year high of $1.74. The stock has a market cap of $18.91 million, a price-to-earnings ratio of -0.31 and a beta of 0.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84.

IN8bio (NASDAQ:INAB) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Hedge Funds Weigh In On IN8bio

A number of large investors have recently bought and sold shares of INAB. Jane Street Group LLC boosted its stake in shares of IN8bio by 296.7% during the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after purchasing an additional 86,696 shares during the period. Geode Capital Management LLC increased its holdings in IN8bio by 56.5% during the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after purchasing an additional 185,919 shares during the period. Sigma Planning Corp raised its position in IN8bio by 22.3% during the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares in the last quarter. Alyeska Investment Group L.P. grew its position in shares of IN8bio by 1,064.5% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after buying an additional 4,628,482 shares in the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of IN8bio in the fourth quarter valued at about $1,465,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.